ROR1 and exocrine pancreatic carcinoma: Previous studies in diffuse large B-cell lymphoma (DLBCL) and small-cell lung cancer (SCLC) have indicated that combining ROR1 inhibitors with venetoclax [30,41,44] or with erlotinib and chemotherapeutics in pancreatic carcinoma [5] acted synergistically to induce tumor cell death.